CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Rising prevalence of human papilloma virus (HPV) infections, causing cancers
3.6.1.2. Increasing administration of prophylactic cancer vaccines
3.6.1.3. Rising investments and government funding in the development of cancer vaccines
3.6.1.4. Launch and approval of new cancer vaccines in the market

3.6.2. Restraints

3.6.2.1. High cost for development of cancer vaccines due to the need of frequent upgradation in manufacturing technology
3.6.2.2. Longer timelines required for manufacturing a single vaccine

3.6.3. Opportunities

3.6.3.1. Increasing transition from prophylactic to therapeutic cancer vaccines
3.6.3.2. High growth prospects in emerging markets

CHAPTER 4 CANCER VACCINES MARKET, BY TECHNOLOGY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. DENDRITIC CELLS CANCER VACCINES

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. RECOMBINANT CANCER VACCINES

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. ANTIGEN/ADJUVANT CANCER VACCINES

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. WHOLE CELL CANCER VACCINES

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. VIRAL VECTOR AND DNA CANCER VACCINES

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

CHAPTER 5 CANCER VACCINES MARKET, BY TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. PREVENTIVE CANCER VACCINES

5.2.1. Market size and forecast

5.3. THERAPEUTIC CANCER VACCINES

5.3.1. Market size and forecast

CHAPTER 6 CANCER VACCINES, BY INDICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. CERVICAL CANCER

6.2.1. Market size and forecast

6.3. PROSTATE CANCER

6.3.1. Market size and forecast

6.4. OTHER INDICATIONS

6.4.1. Market size and forecast

CHAPTER 7 CANCER VACCINES MARKET, BY END USE

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. PEDIATRICS

7.2.1. Market size and forecast

7.3. ADULTS

7.3.1. Market size and forecast

CHAPTER 8 CANCER VACCINES MARKET, BY GEOGRAPHY

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. NORTH AMERICA

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast

8.2.3.1. U.S. market size and forecast
8.2.3.2. Mexico market size and forecast
8.2.3.3. Canada market size and forecast

8.3. EUROPE

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast

8.3.3.1. UK market size and forecast
8.3.3.2. France market size and forecast
8.3.3.3. Germany market size and forecast
8.3.3.4. Italy market size and forecast
8.3.3.5. Spain market size and forecast
8.3.3.6. Rest of Europe market size and forecast

8.4. ASIA-PACIFIC

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast

8.4.3.1. Japan market size and forecast
8.4.3.2. China market size and forecast
8.4.3.3. India market size and forecast
8.4.3.4. Australia market size and forecast
8.4.3.5. Rest of Asia-Pacific market size and forecast

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast

8.5.3.1. Brazil market size and forecast
8.5.3.2. Argentina market size and forecast
8.5.3.3. Turkey market size and forecast
8.5.3.4. South Africa market size and forecast
8.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1. ASTRAZENECA PLC. (MEDIMMUNE, LLC.)

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Business performance
9.1.5. Key strategic moves and developments

9.2. GLAXOSMITHKLINE PLC.

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Business performance
9.2.5. Key strategic moves and developments

9.3. MERCK & CO., INC.

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Business performance
9.3.5. Key strategic moves and developments

9.4. SANOFI PASTEUR

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Business performance
9.4.5. Key strategic moves and developments

9.5. ADURO BIOTECH INC.

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Business performance
9.5.5. Key strategic moves and developments

9.6. SANPOWER GROUP CO., LTD.

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Business performance
9.6.5. Key strategic moves and developments

9.7. ASTELLAS PHARMA INC.

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments

9.8. CSL LIMITED

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Business performance
9.8.5. Key strategic moves and developments

9.9. PFIZER INC.

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Business performance
9.9.5. Key strategic moves and developments

9.10. SERUM INSTITUTE OF INDIA PVT. LTD.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Business performance
9.10.5. Key strategic moves and developments